Bristol Myers Squibb announced the Phase III CheckMate -9DW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy met its primary endpoint of improved overall survival (OS) compared to investigator’s choice of sorafenib or lenvatinib at a pre-specified interim analysis.
LYCLEAR Creme Rinse is indicated for the treatment of infections with the head louse pediculus humanus capitis.
For symptomatic relief of minor pain, itching, and irritation in the following localised skin conditions, such as insect bites, nettle stings, minor skin abrasions, and external genital and external anal itching.
GSK plc announced statistically significant and clinically meaningful overall survival (OS) results from Part 1 and progression-free survival (PFS) results from Part 2 of the RUBY/ENGOTEN6/GOG3031/NSGO phase III trial in adult patients with primary advanced or recurrent endometrial cancer
Janssen Sciences has announced results for its Hepatitis C treatment Olysio plus Sovaldi (simeprevir plus sofosbuvir) in Genotype 1 HCV...
Gilead Sciences has announced topline results from two Phase III studies, FISSION and NEUTRINO, evaluating a 12-week course of the...
For short-term relief of occasional constipation.